Here we report a case of severe everolimus toxicity in a kidney transplant recipient receiving ombitasvir/paritaprevir/ritonavir and dasabuvir combination treatment.
📌 3 Maddede Bu Makale
🎯
Amaç & Hipotez:The incidence of chronic hepatitis C virus (HCV) infection in kidney transplant recipients is 5%-15%, and HCV is an important risk factor for posttransplant kidney issues.
📊
Temel Bulgular & Veri:Novel interferon-free regimens with direct-acting oral antiviral agents have extremely high response rates in solid organ transplant patients with HCV; however, drug–drug interactions, particularly with immunosuppressive agents, should be considered when deciding the treatment.
💡
Sonuç & Katkı:Here we report a case of severe everolimus toxicity in a kidney transplant recipient receiving ombitasvir/paritaprevir/ritonavir and dasabuvir combination treatment.
🔬Tür:Araştırma Makalesi
📍Kapsam:Genişletilmiş Akademik Örneklem
⚙️Değişkenler:Alan Parametreleri
Özet
The incidence of chronic hepatitis C virus (HCV) infection in kidney transplant recipients is 5%-15%, and HCV is an important risk factor for posttransplant kidney issues. Novel interferon-free regimens with direct-acting oral antiviral agents have extremely high response rates in solid organ transplant patients with HCV; however, drug–drug interactions, particularly with immunosuppressive agents, should be considered when deciding the treatment. Here we report a case of severe everolimus toxicity in a kidney transplant recipient receiving ombitasvir/paritaprevir/ritonavir and dasabuvir combination treatment.
🔖
Bu Makaleye Atıf Yap
AKIN, M., BULDUKOĞLU, O. Ç., ADANIR, H., YALÇINKAYA, T., YILMAZ, V. T., YILDIRIM, B., TUNA, Y., SÜLEYMANLAR, İ., DİNÇER, D. (2020). Everolimus Toxicity in a Kidney Transplant Recipient Treated with Ombitasvir/Paritaprevir/Ritonavir and Dasabuvir for Chronic Hepatitis C. Turkish journal of nephrology (Online), Cilt: 29 - Sayı: 1, 82–83. https://ajindex.com/articles/374891
Morales JM, Fabrizi F. Hepatitis C and its impact on renal transplantation. Nat Rev Nephrol 2015; 11: 172-82. [CrossRef] 2. Fabrizi F, Penatti A, Messa P, Martin P. Treatment of hepatitis C after kidney transplant: a pooled analysis of observational studies. J Med Virol 2014; 86: 933-40. [CrossRef] 3. Burgess S, Partovi N, Yoshida EM, Erb SR, Azalgara VM, Hussaini T. Drug Interactions With Direct Acting Antivirals for Hepatitis C: Implications for HIV and Transplant Patients. Ann Pharmacother 2015; 49: 674-87. [CrossRef] 4. Kwo PY, Badshah MB. New hepatitis C virus therapies: drug classes and metabolism, drug interactions relevant in the transplant settings, drug options in decompensated cirrhosis, and drug options in end-stage renal disease. Curr Opin Organ Transplant 2015; 20: 235- 41. [CrossRef] 5. European Association for the Study of the Liver. EASL Recommendations on Treatment of Hepatitis C 2018. J Hepatol 2018; 59: 461- 511. 6. Kaymakoğlu S, Köksal İ, Tabak F, Akarca US, Akbulut A, Akyüz F, et al. Recommendation for treatment of hepatitis C virus infection. Turk J Gastroenterol 2017; 28: 94-100.[CrossRef]